The brake in question sits in the 5ʹ untranslated region, the stretch of RNA that precedes the protein-coding sequence of a transcript. Although it does not encode protein, this region exerts powerful control over how efficiently ribosomes translate the main message. One of its most potent repressive elements is the upstream open reading frame, or uORF, a short alternative reading frame that begins at an upstream start codon and diverts ribosomes away from the true protein. When a ribosome initiates at a uORF and terminates before reaching the main coding sequence, that translation event is wasted. Genes carrying strong uORFs therefore tend to make less protein than their mRNA abundance would predict, and in a haploinsufficient disease that shortfall can tip an individual over the threshold of clinical disease.

Earlier proposals for exploiting this biology focused on steric-block antisense oligonucleotides, synthetic DNA-like molecules that bind to the uORF start codon and physically obstruct ribosome initiation. The approach has shown promise for a handful of specific genes, but its broad applicability has been debated, because the geometry of each uORF differs and blocking initiation is not always feasible or effective. The Oxford-led team, working with colleagues at the International Centre for Genetic Engineering and Biotechnology in Trieste, the University of Exeter and industry partners, pursued a different tactic. Instead of masking the uORF, they asked whether the exon that contains it could be spliced out of the mature mRNA altogether, converting an inhibitory 5ʹUTR into a shorter, permissive one through the cell’s own RNA processing machinery.

To test how widely such an approach might apply, the researchers systematically screened human transcript annotations. Using MANE transcript definitions, the matched annotations agreed upon by NCBI and EMBL-EBI as the definitive reference set for each human gene, they catalogued exons located entirely within 5ʹ untranslated regions whose removal would preserve the reading frame and regulatory logic of the transcript. This analysis yielded 2,210 potentially skippable 5ʹUTR exons. The critical next step was to determine which of those exons actually contain functional uORF start codons, since a start codon annotated in the genome is only repressive if ribosomes genuinely engage with it in living cells.

To make that determination, the team mined ribosome profiling data generated from 13 human tissues and cell lines, including brain, heart and skeletal muscle. Ribosome profiling captures snapshots of ribosome positions across the transcriptome, allowing researchers to distinguish start codons that are actively used from those that are silent. Applying this filter, the researchers identified 1,056 skippable 5ʹUTR exons harbouring translated uORF start codons. Crucially, 79 of these exons sit in genes already classified as haploinsufficient monogenic disease genes in expert-curated resources such as ClinGen, the Gene Curation Coalition and Gene2Phenotype. In other words, a defined, immediately clinically relevant target list already exists, and the authors suggest it could serve as a roadmap for precision medicines across dozens of rare disorders.

From that list the team prioritised six candidate exons in genes linked to neurodevelopmental disorders, a therapeutic area where haploinsufficiency is common and where the blood–brain barrier complicates conventional protein replacement. They constructed dual luciferase reporter assays in which the native 5ʹUTR of each target gene drives a measurable enzyme, then compared translation when the candidate exon was removed. For four of the six genes—CTCF, GRIN2B, KRIT1 and TSC1—skipping the target exon significantly boosted downstream protein production, with increases ranging from 1.4-fold to 5.5-fold. That magnitude matters, because many haploinsufficient disorders are thought to respond to even modest restoration of gene dosage, and a twofold increase in protein output would be transformative for conditions in which patients carry essentially half of the normal complement.

A key mechanistic question was whether the benefit came from removing the uORF itself or from other regulatory elements embedded in the skipped exons, such as RNA structures, microRNA sites or RNA-binding protein motifs that might independently suppress translation. To disentangle these effects, the researchers created reporters in which only the uORF start codons were mutated, leaving the rest of the exon sequence intact. Removing the start codons alone increased translation to comparable or even greater levels, between 1.4-fold and 7.9-fold, indicating that the uORF is the dominant repressive element in these exons. For TSC1, the gene mutated in a subset of tuberous sclerosis complex cases, the team went further and showed that multiple uORFs act additively, with each additional upstream reading frame further depressing protein output from the main coding sequence.

The most clinically significant experiment involved splice-switching antisense oligonucleotides, shortened to SSOs. These chemically modified oligonucleotides bind pre-mRNA sequences such as splice donor or acceptor sites and trick the cellular splicing machinery into excluding a chosen exon. The researchers designed SSOs against the prioritised TSC1 5ʹUTR exon and demonstrated that treatment induced the intended exon skipping in cells and up-regulated levels of the endogenous TSC1 protein, produced from the cell’s own genomic copy rather than from a reporter construct. This is the decisive proof of concept: it shows that the strategy works not just on engineered sequences but on the authentic genomic context of a real disease gene, using a drug modality—antisense oligonucleotides—that already has an established clinical track record in spinal muscular atrophy, Duchenne muscular dystrophy and other conditions.

Splice-switching antisense technology brings genuine advantages for rare disease. Because ASOs can be designed rationally from the genomic sequence, a bespoke candidate can be developed quickly for an individual gene or even an individual patient, an approach that has already produced landmark personalised treatments for ultra-rare genetic conditions. The Oxford team’s systematic catalogue of 1,056 uORF-bearing skippable exons effectively converts that bespoke potential into a scalable pipeline: identify the haploinsufficient gene, check whether it carries a skippable 5ʹUTR exon with an active uORF, design an SSO, and titrate protein output back toward normal. The authors argue that their findings support the broad application of 5ʹUTR exon skipping as a general therapeutic mechanism for upregulating protein production from clinically relevant haploinsufficient genes.

Important caveats remain before patients benefit. The four of six prioritised exons that did not respond uniformly remind the field that uORF architecture varies, and that some 5ʹUTR exons may contain activating elements whose loss could be harmful. Delivery to the brain and other tissues, dose control, and the safety of chronically boosting dosage of tumour-suppressor-class genes such as TSC1 and CTCF will all require careful preclinical and clinical evaluation. The translational potential has nonetheless attracted commercial interest: several of the authors hold patents on uORF-targeting technologies and exon-skipping approaches licensed to a University of Oxford spin-out, and the work draws on genomic data from hundreds of thousands of participants in the UK’s National Genomic Research Library. If the approach clears those hurdles, the humble untranslated region—a stretch of RNA long treated as a footnote to the genetic code—may become one of the most promising drug targets in rare disease medicine.

Subject of Research: Using splice-switching antisense oligonucleotides to skip uORF-containing 5ʹ untranslated region exons and upregulate protein expression from haploinsufficient disease genes.

Article Title: Modulating splicing in 5ʹ untranslated regions to treat rare haploinsufficient disease

Article References: Beer Wells, E. S., De Conti, L., Kim, H. C., Rohani, N., Chundru, K., Svrzikapa, N., McClorey, G., Watts, L. M., Dawes, R., Chen, Y., Martin-Geary, A. C., Griffiths, M. J., Scott, S., Bamford, R. A., Wood, M. J., Roberts, T. C., Mill, J., Wright, C. F., Baralle, M., … Whiffin, N. (2026). Modulating splicing in 5ʹ untranslated regions to treat rare haploinsufficient disease. Genome Medicine. https://doi.org/10.1186/s13073-026-01773-0

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01773-0

Keywords: rare disease, haploinsufficiency, antisense oligonucleotides, 5ʹ untranslated region, upstream open reading frames, splicing, therapeutic upregulation, TSC1, CTCF, GRIN2B, neurodevelopmental disorders, Genome Medicine

Argonaute proteins function by loading siRNAs, which guide these molecular scissors to complementary sequences on target RNAs. The hallmark of AGO-clade Argonautes is their stringent requirement for near-perfect base pairing between siRNA and target RNA, facilitating cleavage precisely at the matched site. However, a paradox exists: AGO proteins possess a constricted nucleic acid-binding channel that limits extensive base pairing beyond a critical “seed” region, typically encompassing the first 2 to 8 nucleotides from the 5′ end of the guide siRNA. This structural feature appeared at odds with the experimental demonstration that extensive pairing beyond the seed is often necessary for catalytic cleavage efficiency. The conundrum of how AGO–siRNA complexes overcome this apparent steric limitation to enable effective slicing has now been brought into sharp focus.

The team led by Li and colleagues embarked on a meticulous cryo-EM investigation of human AGO2 loaded with siRNAs bound to target RNAs of incrementally increasing length. This high-resolution structural approach permitted the visualization of distinct molecular states along the binding and cleavage pathway. Initial observations showed that upon target RNA engagement, AGO2 initiates a conformational shift beginning with the opening of the PAZ domain—a specialized region known to bind the 3′ end of the siRNA. This opening is not an isolated event; rather, it propagates through the protein architecture, orchestrating a repositioning of the composite PIWI–L1–N domain ensemble toward the siRNA–target duplex.

This repositioning is pivotal because it facilitates the capture and stabilization of the growing siRNA–target RNA helix within AGO2’s nucleic acid-binding channel, a crucial step to evading the physical constraints imposed by the narrow passageway. As base pairing between the guide and the target extends beyond the seed region, further conformational dynamics ensue. The PIWI–L1–N domain, previously nudged closer, undergoes a downward movement perpendicular to the binding channel, effectively priming the catalytic site within AGO2. This repositioning aligns the scissile phosphate of the target RNA within reach of catalytic residues, setting the stage for precise endonucleolytic cleavage.

Intriguingly, the structural data disclosed an unexpected architectural rearrangement upon even further base pairing beyond the 3′ end of the siRNA. The PAZ domain and the adjacent N domain become destabilized, culminating in a “uni-lobed” conformation of the AGO2 complex. This architectural switch appears to relax the complex into a more open and single-lobed state compared to the “bilobed” appearance observed in early binding stages. The authors theorize that this uni-lobed structure plays a functional role beyond mere structural rearrangement—potentially facilitating multi-turnover catalysis, whereby AGO2 can dissociate cleaved product RNA and engage subsequent targets rapidly and efficiently.

The elucidation of this multi-step mechanism reconciles prior biophysical and biochemical data that hinted at dynamic flexibility within AGO2 but lacked direct structural corroboration. Moreover, when contrasted with PIWI-clade Argonautes—another evolutionary branch specialized for piRNAs—the AGO2 uni-lobed form exhibits distinct contact patterns with the central region of the siRNA–target duplex. In PIWI proteins, the target RNA is engaged differently, reflecting their divergent biological roles and cleavage modalities. This comparative insight broadens our understanding of how Argonaute proteins, derived from a common ancestral origin, have evolved specialized mechanisms tailored to their unique RNA targets and cellular functions.

Beyond its structural revelations, the research has significant implications for RNA interference (RNAi)-based therapeutic strategies. Understanding exactly how AGO2 accommodates extensive base pairing with target RNAs under spatial constraints can guide the rational design of siRNAs with improved specificity and cleavage efficiency. Potentially, this could reduce off-target effects and enhance the potency of RNAi drugs. Additionally, discovering the uni-lobed state opens a new conceptual avenue for modulating AGO2 activity, possibly through small molecules or engineered proteins that stabilize or destabilize specific conformations to influence catalytic turnover.

These findings also resonate with burgeoning interests in programmable RNA-guided enzymes beyond CRISPR systems. AGO2 exemplifies a naturally evolved RNA-guided nuclease optimized through millions of years of molecular tinkering, and leveraging its mechanistic nuances promises novel biotechnological applications. For example, artificial siRNA designs that exploit the conformational transitions described might be employed to regulate gene expression with unprecedented precision or generate synthetic systems with tailored catalytic cycles.

Importantly, this study underscores the power of cryo-EM as a transformative technique in molecular biology, enabling the capture of transient intermediates and dynamic conformational ensembles previously inaccessible to structural methods like X-ray crystallography. By capturing AGO2–siRNA complexes bound to targets of varying length, the researchers constructed a quasi-movie of the recognition and cleavage process, marking a milestone in our structural and mechanistic understanding of RNA-guided cleavage enzymes.

The research by Li and colleagues not only fills a critical knowledge gap but also invites new questions. For instance, how is the transition to the uni-lobed form regulated within the cellular milieu? Are there auxiliary factors or post-translational modifications that influence AGO2’s conformational landscape or turnover rates? Furthermore, does this mechanism vary across different human Argonaute paralogs, or does it represent a universal paradigm for AGO-mediated target cleavage?

In sum, the detailed mechanistic insight offered into the stepwise conformational adaptation of the human AGO2–siRNA complex during target RNA cleavage advances our grasp of RNA interference at the atomic level. By unraveling how structural domains coordinate to bypass nucleic acid-binding channel constraints and enable enzymatic action, this work charts a clear path forward for both fundamental biology and therapeutic innovation. As the molecular narrative of Argonaute proteins continues to unfold, such landmark discoveries illuminate the exquisite molecular engineering that sustains life’s precise control over genetic information.

Subject of Research:
Mechanistic elucidation of human Argonaute2–siRNA complex conformational dynamics and target RNA cleavage.

Article Title:
Mechanistic insights into RNA cleavage by human Argonaute2–siRNA complex.

Article References:
Li, Z., Xu, Q., Zhang, Y. et al. Mechanistic insights into RNA cleavage by human Argonaute2–siRNA complex.
Cell Res (2025). https://doi.org/10.1038/s41422-025-01114-7

Image Credits: AI Generated